Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

54.67USD
9:44pm IST
Price Change (% chg)

$0.27 (+0.50%)
Prev Close
$54.40
Open
$54.56
Day's High
$54.89
Day's Low
$54.42
Volume
174,004
Avg. Vol
634,045
52-wk High
$55.70
52-wk Low
$36.26

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.65
Market Cap (Mil.): $51,850.31
Shares Outstanding (Mil.): 951.29
Dividend: 0.35
Yield (%): 3.05

Financials

  TEVA.N Industry Sector
P/E (TTM): 33.38 35.65 36.07
EPS (TTM): 1.63 -- --
ROI: 3.93 18.91 18.18
ROE: 6.06 19.67 19.05
Search Stocks

Teva to name new chairman - activist investor Landa says

TEL AVIV, July 14 - Teva Pharmaceutical Industries board is to appoint vice-chairman Amir Elstein as its new chairman, activist shareholder Benny Landa said on Monday.

14 Jul 2014

UPDATE 2-EU fines 6 drug firms 428 mln euros for blocking cheaper drugs

* Six companies get combined penalty of 428 million euros

09 Jul 2014

EU regulators fine Servier, Teva, others 428 mln euros

BRUSSELS, July 9 - European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others 427.7 million euros ($583.40 million) on Wednesday for blocking cheaper generic medicine.

09 Jul 2014

Teva files petition with U.S. FDA against MS drug competitors

TEL AVIV, July 3 - Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration (FDA), aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis (MS).

03 Jul 2014

UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions

(Adds details of drugs to be divested, share price, other pharma deals)

01 Jul 2014

EU to fine Servier, Teva for delaying generic drugs - sources

BRUSSELS, June 19 - EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.

19 Jun 2014

UPDATE 1-Teva Pharm's chairman Phillip Frost to step down by year end

* Teva shares up 0.7 percent in New York (Adds details, background, share reaction)

18 Jun 2014

Teva Pharm chairman Frost to step down by year end

TEL AVIV, June 18 - Phillip Frost, chairman of the world's biggest generic drugmaker Teva Pharmaceutical Industries , said on Wednesday he will step down by the end of this year.

18 Jun 2014

Teva launching 3 drugs in 2014 with combined peak sales of $1 bln

TEL AVIV - Teva Pharmaceutical Industries is launching three new products in 2014 with combined estimated peak sales of $1 billion, the chief executive of the world's biggest generic drugmaker said on Tuesday.

20 May 2014

Teva launching 3 drugs in 2014 with combined peak sales of $1 bln

TEL AVIV, May 20 - Teva Pharmaceutical Industries is launching three new products in 2014 with combined estimated peak sales of $1 billion, the chief executive of the world's biggest generic drugmaker said on Tuesday.

20 May 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF80.00 +0.60
Biogen Idec Inc (BIIB.OQ) $341.68 +5.29

Earnings vs. Estimates

Search Stocks